Inflammation resolution — what's supposed to happen after the inflammatory response
6 min read · Uplevel editorial
You cut your finger and it swells. Redness, warmth, pain, swelling — the four classical signs of inflammation, described by the Roman physician Celsus two thousand years ago. Three days later the swelling is gone, the pain is gone, the skin is repairing, and life continues. This outcome is so routine we don't think of it as biology. It is, in fact, extraordinarily sophisticated biology, and for most of the twentieth century, medicine got a fundamental part of it wrong.
The assumption, embedded in pharmacology and immunology for decades, was that inflammation resolution is passive. The acute response ramps up, and then — when the stimulus is removed — it winds back down on its own. The drugs developed to manage inflammation were mostly suppressors of the initiation phase: aspirin blocking prostaglandin synthesis, corticosteroids broadly suppressing immune activation, biologics neutralizing specific cytokines. The underlying model was: inflammation is the problem, and the solution is to dampen or block it.
What Charles Serhan's laboratory at Harvard Medical School began demonstrating in the 1990s — and has been methodically building the evidence for ever since — is that resolution is not passive cessation. It is an active, programmed biological process, governed by a distinct class of molecules that the body synthesizes specifically to bring inflammation to an end, clear the cellular wreckage, and initiate tissue repair. These molecules — lipoxins, resolvins, protectins, and maresins — are collectively called specialized pro-resolving mediators, or SPMs. They are produced from the same precursor fatty acids as the pro-inflammatory eicosanoids, but they do something categorically different: they actively shut down the inflammatory response, promote the clearance of dead cells and debris, and signal the transition to repair. Resolution, in this understanding, is not the absence of inflammation. It is a parallel biological program that runs alongside inflammation and — if it is working correctly — terminates it on schedule.
The chemistry is worth understanding because it changes how you think about chronic inflammation. The pro-inflammatory phase of the acute response involves the conversion of arachidonic acid — an omega-6 fatty acid — into prostaglandin E2 (PGE2) and leukotrienes via the COX and LOX enzyme pathways. PGE2 drives vasodilation and sensitizes pain receptors; leukotrienes recruit neutrophils to the inflammatory site. Aspirin and ibuprofen work by inhibiting COX enzymes, reducing PGE2 production, and thereby blunting the acute inflammatory signal. This can be appropriate for acute pain management. But aspirin also — in a separate action — triggers the conversion of arachidonic acid and EPA into aspirin-triggered lipoxins, which are resolution compounds. The COX inhibition pathway and the resolution-triggering pathway share the same enzyme.
Resolvins are derived from EPA and DHA — the omega-3 fatty acids found in cold-water fish and algae. E-series resolvins come from EPA; D-series resolvins from DHA. Protectins (also called neuroprotectins when acting in neural tissue) come from DHA. Maresins come from DHA as well, produced specifically by macrophages. These molecules operate at nanomolar concentrations — they are extraordinarily potent — and they act on specific receptors on immune cells to do several things at once: stop the further recruitment of neutrophils to the inflammatory site, shift macrophage behavior from the pro-inflammatory M1 phenotype to the pro-resolving M2 phenotype, promote efferocytosis (the process by which dead and dying cells are cleared from tissue), and stimulate tissue-resident stem cells and repair mechanisms to begin rebuilding what was damaged. Resolution is active in a very literal sense — it requires energy, enzymatic activity, receptor signaling, and cellular behavior change. It does not happen automatically and it can fail.
When resolution fails, or is chronically insufficient, you do not get repeated acute inflammation. You get the particular kind of inflammation that characterizes most chronic disease: low-grade, persistent, not fully activated but also never turned off. The neutrophils that should have cleared out are still present. The macrophage populations are stuck in an inflammatory activation state. The tissue that should have repaired has instead been replaced by fibrosis or become the seat of persistent immune activity. This is the inflammatory background of atherosclerosis, of type 2 diabetes, of rheumatoid arthritis, of many neurodegenerative diseases, of chronic pain syndromes. The problem in each of these conditions may not be primarily that the inflammatory initiation signal is too strong. The problem may be that the resolution program is inadequate.
This reframing has clinical implications that are not yet fully reflected in treatment approaches. If chronic inflammation is a resolution failure, then the appropriate intervention is not just more suppression of the initiation phase — it is supporting the resolution machinery. NSAIDs and biologics reduce symptoms and may prevent certain downstream damage, but they do not restore resolution. They reduce the inflammatory signal but do nothing for the clearance of dead cells, the repair of tissue, or the restoration of immune homeostasis. An analogy: if a fire alarm is going off continuously, silencing the alarm addresses the symptom but not the smoldering fire.
Serhan's work on SPMs has attracted attention from pharmaceutical development, and there are early-stage human trials exploring SPM precursors and synthetic SPM analogs for inflammatory conditions. This work is ongoing and the clinical translation remains incomplete. What is immediately actionable is the upstream observation: SPMs are derived from omega-3 fatty acids, which means that omega-3 status is a substrate-level determinant of the body's resolution capacity. A person whose diet provides very little EPA and DHA has less raw material available for resolvin and protectin synthesis. This is not a conditional association — it is a direct biochemical dependency. The resolution program requires the precursors.
The omega-3 to omega-6 ratio matters in this context, though the framing requires care. The relevant point is not that omega-6 fatty acids are inherently inflammatory — linoleic acid, the primary dietary omega-6, is not a direct inflammatory driver and the evidence for dietary omega-6 restriction improving health outcomes is weak. The relevant point is that EPA and DHA specifically are the limiting precursors for SPM synthesis, and most Western diets provide very little of them while providing large amounts of arachidonic acid precursors through grain-fed meat and seed oils. Estimates of ancestral omega-3 to omega-6 intake ratios vary widely — the specific numbers are contested — but the direction is clear: contemporary Western diets are significantly lower in EPA and DHA than the diets in which human omega-3 physiology evolved. The population-level insufficiency of EPA and DHA is real and well-documented in dietary surveys.
Cold-water fatty fish — salmon, mackerel, sardines, anchovies, herring — are the most bioavailable sources of EPA and DHA. Algae-derived omega-3 supplements provide DHA directly from the photosynthetic organisms at the base of the food chain (this is where fish get their DHA; they accumulate it by eating algae) and are a viable option for people who don't eat fish.
Diet is not the only lever on resolution biology. Regular exercise has been studied for its capacity to enhance SPM production and shift macrophages toward the pro-resolving phenotype, which may be part of why physically active people tend to carry a lower chronic inflammatory burden. Sleep matters too: the slow-wave stages of sleep appear to support the resolution and clearance processes that follow an inflammatory episode, and inadequate deep sleep has been associated with impaired resolution and elevated baseline inflammation. On the pharmaceutical side, the clearest regulatory milestone is icosapent ethyl — a purified, high-dose EPA ester marketed as Vascepa — which the FDA has approved to reduce cardiovascular risk in specific populations with elevated triglycerides. It is approved on the basis of cardiovascular outcomes rather than as a resolution drug per se, but its mechanism runs directly through EPA, the same omega-3 precursor from which the E-series resolvins are synthesized — consistent with the broader picture that EPA and DHA availability shapes the body's resolution capacity.
Seen through the lens of resolution biology, omega-3 intake stops being just a cardiovascular talking point. It is the raw material the body draws on to end inflammation on schedule, clear the cellular wreckage, and begin repair — which means adequate EPA and DHA status may help support the resolution capacity that so many chronic, low-grade inflammatory conditions appear to lack. The question worth carrying forward is not only how to suppress inflammation, but whether the body has what it needs to finish resolving it.
Frequently asked